Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.

Taipei Medical University80 enrolled

Overview

Nattokinase has been confirmed by many experiments to have a thrombolytic effect, but there are currently very few studies on nattokinase's effect on gut microbiota, sleeping status, and age-related cognitive function. Therefore, this study intends to explore the effect of nattokinase on cardiovascular disease risk factors, intestinal microbiota, sleep status and cognitive function in patients with metabolic syndrome risk and sleep disorders. This study will be a double-blind, self-control, placebo, crossover trial, and recruit 70-80 participants over 18 years old, and have risk of metabolic syndrome and sleep disorders. They will be divided into a placebo group and an experimental group. The experimental period was divided into two phases (12 weeks for each) and a 2-week washout period. In the first phase, 2 placebo or nattokinase capsules were given each day (each capsule contained nattokinase 3000FU, 2 capsules per day). After 12 weeks, a 2-week washout period was entered, and the second phase was entered for a crossover trial. At the 0th and 12th weeks of each stage, body position, blood pressure, blood biochemical values, sleep quality questionnaire, and cognitive function questionnaire will be measured, and feces will be collected for bacterial analysis. In addition, to improve the compliance of the trial, it is planned to ask the subjects to return for a follow-up visit in the 6th week of each phase, and to measure the subject's body composition and blood pressure. This study expects that daily supplementation of 2 nattokinase capsules for 12 weeks can improve cardiovascular risk factors, sleep quality and cognitive function, while also maintaining healthy intestinal flora.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Interventions

NattokinaseDIETARY_SUPPLEMENT

Participants will be divided into a placebo group and an experimental group. The experimental period was divided into two phases (12 weeks for each) and a 2-week washout period. In the first phase, 2 nattokinase capsules were given each day (each capsule contained nattokinase 3000FU, 2 capsules per day). After 12 weeks, a 2-week washout period was entered, and the second phase was entered for a crossover trial.

PlaceboOTHER

Participants will be divided into a placebo group and an experimental group. The experimental period was divided into two phases (12 weeks for each) and a 2-week washout period. In the first phase, 2 placebo capsules were given each day (each capsule contained Microcrystalline Cellulose, 2 capsules per day). After 12 weeks, a 2-week washout period was entered, and the second phase was entered for a crossover trial.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Over 18 years old 2. Meet the criteria of MetS: meet at least two of the following four items will be recognized as at risk of metabolic syndrome: 1. Abdominal obesity: Male≧90cm (35 inches); Female≧80cm (31inches) 2. High blood pressure: Systolic blood pressure≧120mmHg or diastolic blood pressure≧80mmHg 3. High fasting blood glucose: Fasting blood glucose≧100mg/dL 4. Dyslipidemia: High fasting triglycerides (≧150mg/dL) or low high-density lipoprotein cholesterol (HDL-C) (\<40mg/dL for male, \<50mg/dL for female) 3. The Apnea Hypopnea Index (AHI) was diagnosed by overnight multi-channel sleep physiology examination (Polysomnography, PSG) or Home Sleep Apnea Test (HSAT) to be between 5 and 30, indicating mild or moderate sleep apnea. 4. No major mental illness or obvious symptoms of anxiety or depression 5. No combination with other primary sleep diseases Exclusion Criteria: 1. Body mass index (BMI) \>30 kg/m\^2 2. Chronic diseases: abnormal liver and kidney function, abnormal gastrointestinal function, cardiovascular disease, high blood pressure, diabetes mellitus, and hyperlipidemia, etc. 3. Participants requiring medication for conditions not specified in exclusion criterion (2), who are unable to maintain a stable treatment regimen throughout the trial 4. Malignant tumors 5. Pregnancy or breastfeeding 6. Person expected to perform the surgery. 7. Those who have participated in other clinical trials in the past 28 days. 8. May be allergic to the ingredients in the test materials, or take drugs or dietary supplements that may affect the test results

Outcomes

Primary Outcomes

Change from Baseline The Pittsburgh Sleep Quality Index (PSQI) at 3 months

PSQI is used to evaluate sleeping quality. A self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline Insomnia Severity Scale at 3 months

ISI is a simple self-assessment questionnaire for evaluating the severity of insomnia, assessing the severity of insomnia over the past two weeks in the study participants.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline Epworth Sleepiness Scale (ESS) at 3 months

ESS is a self-administered questionnaire, and is used to assess the "daytime sleepiness" of the patients.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline Patient Health Questionnaire at 3 months

PHQ-9 is a widely used tool for assessing depressive symptoms in both clinical and research settings, evaluating the severity of depressive symptoms over the past two weeks through 9 questions.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline Generalized Anxiety Disorder at 3 months

GAD-7 is a brief self-report scale specifically designed to assess the frequency and severity of anxiety symptoms over the past two weeks.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline Oguri-Shirakawa-Azumi Sleep Inventory MA version at 3 months

OSA Sleep Inventory MA version is a psychological measurement tool suitable for clinical settings and for middle-aged and elderly individuals who are unable to appropriately respond to multiple-choice questions, used to assess an individual's self-evaluation of sleep upon waking.

Time frame: At 0th week, and 12th week for each of the two phases.

Change from Baseline The Cambridge Neuropsychological Test Automated Battery at 3 months

CANTAB (Cambridge Neuropsychological Test Automated Battery) is a computerized cognitive function testing system developed by the University of Cambridge, This study will use the preclinical dementia test battery recommended by CANTAB. This test battery has been proven to have better sensitivity and discriminative ability compared to traditional assessment methods including ADAS-cog and MMSE, and can detect cognitive function changes in the short to medium term. The overall assessment includes the following 7 subtests: 1. Motor Screening Task (MOT) 2. Reaction Time (RTI) 3. Paired Associates Learning (PAL) 4. Spatial Working Memory (SWM) 5. Pattern Recognition Memory (PRM) 6. Delayed Matching to Sample (DMS) 7. Rapid Visual Information Processing (RVP)

Time frame: At 0th week, and 12th week for each of the two phases.

Secondary Outcomes

Anthropometric Assessment

body weight (kg)

Time frame: At 0th week, 6th week, and 12th week for each of the two phases.

Anthropometric Assessment

Body fat mass (%/kg)

Time frame: At 0th week, 6th week, and 12th week for each of the two phases.

Anthropometric Assessment

Skeletal muscle mass (%/kg)

Time frame: At 0th week, 6th week, and 12th week for each of the two phases.

Blood pressure

blood pressure (mmHg)

Time frame: At 0th week, 6th week, and 12th week for each of the two phases.

Liver Function

Serum AST (U/L)

Time frame: At 0th week, and 12th week for each of the two phases.

Liver Function

Serum ALT (U/L)

Time frame: At 0th week, and 12th week for each of the two phases.

Kidney Function

Serum BUN (mg/dL)

Time frame: At 0th week, and 12th week for each of the two phases.

Kidney Function

Creatinine (mg/dL)

Time frame: At 0th week, and 12th week for each of the two phases.

Kidney Function

eGFR (mL/min)

Time frame: At 0th week, and 12th week for each of the two phases.

Kidney Function

uric acid (mg/dL)

Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts